We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+5.45%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$3.11B
AUM Growth
+$2.21M
Cap. Flow
-$39.8M
Cap. Flow %
-1.28%
Top 10 Hldgs %
35.29%
Holding
188
New
16
Increased
26
Reduced
40
Closed
17

Top Buys

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$35.7M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$32.2M
3
MRNA icon
Moderna
MRNA
+$25.5M
4
DHR icon
Danaher
DHR
+$16.7M
5
RMD icon
ResMed
RMD
+$15.7M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$25.3M
2
EXAS
Exact Sciences
EXAS
+$21.5M
3
CTLT
CATALENT, INC.
CTLT
+$19.2M
4
XRAY icon
Dentsply Sirona
XRAY
+$17.1M
5
CI icon
Cigna
CI
+$16.6M

Sector Composition

Rank Sector Weight
1 Healthcare 96.33%
2 Real Estate 2.82%
3 Industrials 0.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ASND icon
76
Ascendis Pharma A/S
ASND
$16B
$9.12M 0.29%
67,794
– –
OHI icon
77
Omega Healthcare
OHI
$14.8B
$9.07M 0.29%
306,433
– –
ARWR icon
78
Arrowhead Research
ARWR
$12.1B
$8.94M 0.29%
134,812
-69,402
-34% -$4.77M
ADUS icon
79
Addus HomeCare
ADUS
$2.16B
$7.82M 0.25%
83,632
– –
UHS icon
80
Universal Health Services
UHS
$10.4B
$7.78M 0.25%
60,023
– –
NBP
81
NovaBridge Biosciences American Depositary Shares
NBP
$185M
$7.71M 0.25%
162,580
– –
AMN icon
82
AMN Healthcare
AMN
$1.35B
$7.49M 0.24%
+61,201
New +$6.79M
TBPH icon
83
Theravance Biopharma
TBPH
$874M
$7.25M 0.23%
656,296
– –
ARVN icon
84
Arvinas
ARVN
$516M
$7.06M 0.23%
85,997
– –
SBRA icon
85
Sabra Healthcare REIT
SBRA
$5.29B
$6.91M 0.22%
510,660
– –
NTLA icon
86
Intellia Therapeutics
NTLA
$1.51B
$6.88M 0.22%
58,180
– –
ELV icon
87
Elevance Health
ELV
$81.7B
$6.79M 0.22%
14,644
– –
RVTY icon
88
Revvity
RVTY
$12.9B
$6.72M 0.22%
33,444
– –
TVTX icon
89
Travere Therapeutics
TVTX
$5.12B
$6.61M 0.21%
212,869
– –
ALKS icon
90
Alkermes
ALKS
$8.43B
$6.45M 0.21%
277,309
-96,515
-26% -$2.54M
A icon
91
Agilent Technologies
A
$39.3B
$6.33M 0.2%
39,625
– –
SNN icon
92
Smith & Nephew
SNN
$13.5B
$6.29M 0.2%
181,710
– –
LTC
93
LTC Properties
LTC
$2.03B
$6.22M 0.2%
182,293
– –
SNY icon
94
Sanofi
SNY
$103B
$6.18M 0.2%
123,454
-29,800
-19% -$1.47M
PHG icon
95
Philips
PHG
$25.6B
$6.07M 0.2%
199,498
– –
QGEN icon
96
Qiagen
QGEN
$8.71B
$6M 0.19%
101,713
– –
DOC icon
97
Healthpeak Properties
DOC
$15.1B
$5.43M 0.17%
150,392
– –
IONS icon
98
Ionis Pharmaceuticals
IONS
$8.85B
$5.35M 0.17%
175,680
-146,841
-46% -$4.62M
RCM
99
DELISTED
R1 RCM Inc. Common Stock
RCM
$5.16M 0.17%
202,351
– –
VRNA
100
DELISTED
Verona Pharma
VRNA
$5.05M 0.16%
751,905
– –
2 3
4
5 6

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q4 2021 Portfolio in Review

As of Q4 2021, Tekla Capital Management held 188 positions worth $3.11B, up 0.07% from $3.11B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Tekla Capital Management's Q4 2021 filing shows 16 new, 26 increased, 40 reduced and 17 closed positions. Its largest new stake was AMN Healthcare: 61,201 shares worth $7.49M. The largest sale was Biogen, an estimated $25.3M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 97% a quarter earlier, followed by Real Estate and Industrials.

  • Tekla Capital Management's largest Q4 2021 buy was AMN Healthcare: 61,201 shares worth $7.49M.
  • Tekla Capital Management added most to Pfizer in Q4 2021, an estimated $35.7M increase.
  • Tekla Capital Management's biggest Q4 2021 reduction was Biogen, cutting an estimated $25.3M.
  • Tekla Capital Management fully exited Exact Sciences in Q4 2021, selling an estimated $21.5M.
  • Tekla Capital Management's ten largest holdings make up 35% of its $3.11B portfolio in Q4 2021.
  • Tekla Capital Management opened 16 new positions and closed 17 in Q4 2021.
  • Tekla Capital Management's portfolio value rose 0.07% quarter-over-quarter to $3.11B.

Based on Tekla Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.